On January 28, Novartis AG (NVS.US) announced that its first-in-class small interfering RNA cholesterol-lowering drug, Leqvio® (Inclisiran Sodium Injection), has received approval from China's National Medical Products Administration (NMPA). The new approval is for use as an adjunct to diet, either as a monotherapy in adult patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia, to lower low-density lipoprotein cholesterol (LDL-C). Building upon its previously approved indications for use in combination with statins, or with statins and other lipid-lowering therapies, Inclisiran now extends its reach to cover a broader population of patients with dyslipidemia in need. As the world's first and currently only approved small interfering RNA cholesterol-lowering drug targeting PCSK9, Inclisiran's dosing regimen of two injections per year is expected to enhance treatment adherence and long-term LDL-C达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标率达标 rate, thereby aiding in the achievement of long-term standardized lipid management.